Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

20 November 2023

Antibiotic resistance a looming, deadly global threat

For Deutsche Welle, Fabian Schmidt writes about the threat posed by antibiotic-resistant bacteria and the need to develop new antibiotic drugs. The article spotlights the Foundation's work on antimicrobial resistance (AMR).

Direct links

Read the full article

The article* highlights the alarming threat antibiotic-resistant bacteria pose to global health and the insufficient efforts by pharmaceutical companies to develop new antibiotics. Schmidt writes that while AMR affects both developed and developing countries, its impact is most severe in the western sub-Saharan Africa.

He emphasises that large corporations are responsible for manufacturing over 200 antibiotic products supplied worldwide. Halting the production of antibiotics by these companies would result in millions of deaths in low- and middle-income countries due to lack of access to appropriate medication.

Schmidt references the Foundation's research on AMR, which finds that there is an urgent need for antibiotics in over 100 countries globally, and highlights the Foundation's call for more research into new antibiotics by pharmaceutical companies.

*This article was also featured in Hindustan Times.

Cross-sector Research

Learn more about our work on AMR
Featured News

The 2021 AMR Benchmark pinpointed opportunities for companies. Did they take them?

21 November 2023
News

What steps are companies taking to help curb AMR by manufacturing responsibly?

22 August 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved